Facebook Twitter LinkedIn Google Plus RSS

Hackensack Meridian's Pecora notches coveted BioNJ award

By ,
BioNJ president Debbie Hart (middle, red dress) poses with representatives of the 26 companies that received innovation awards during BioNJ's gala 25th anniversary awards event, Feb. 1.
BioNJ president Debbie Hart (middle, red dress) poses with representatives of the 26 companies that received innovation awards during BioNJ's gala 25th anniversary awards event, Feb. 1. - ()

Dr. Andrew Pecora, chief innovation officer at Hackensack Meridian Health and founder of Children’s Organ Transplant Association, became the first practicing physician to be awarded the Dr. Sol J. Barer award from biopharmaceutical industry trade group BioNJ.

The award, which has always been given to CEOs of biopharma companies in New Jersey, is named after the founder and former CEO of Celgene Corp. and was given to Pecora for his innovations in value-based health care and health care administration, and for his expertise and innovation in stem cell transplantation, cellular medicine and immunology research.

“I am extremely honored and humbled to receive the Sol J. Barer award for vision, innovation and leadership from BioNJ, considering the accomplishments of the awards namesake and all of the other prior distinguished awardees,” said Pecora in his acceptance speech. “… Tonight, on its 25th anniversary, BioNJ has convened all of us to accelerate our collective mission to have New Jersey, lead our nation and the world in innovation to find more cures and relieve more suffering because patients can’t wait.”

Debbie Hart, BioNJ’s president, presented Pecora with the award during BioNJ’s 25th anniversary gala and awards ceremony Feb. 1 in New Brunswick.

In her remarks, Hart said New Jersey’s biopharma industry made great strides in 2017 with the introduction of groundbreaking new and medications and treatment therapies.

“We look forward to a bright future in 2018 and beyond,” she said.

The winners

BioNJ awarded 26 biopharma companies for introducing new drugs and treatments in 2017 for a vast array of diseases and conditions, including cancer, diabetes, irritable bowel syndrome and hepatitis. Those companies are:

Aerie Pharmaceuticals

PTC Therapeutics Inc.

Allergan

Merck & Co.

Bausch & Lomb

Mitsubishi Tanabe

Bayer Healthcare Pharmaceuticals

Novartis Pharmaceuticals

Celgene Corp.

Novo Nordisk

Eli Lilly & Co.

Otsuka Pharmaceutical

GlaxoSmithKline

Pfizer Inc.

Janssen Biotech

Radius Health

Jazz Pharmaceuticals

Sanofi

Kedrion Biopharma

Shionogi Inc.

Kite Pharma Inc.

Symbiomix Therapeutics LLC

Lexicon Pharmaceuticals

Teva Pharmaceuticals

The Medicines Co.

Valeant Pharmaceuticals

More From This Industry

Vince Calio

Vince Calio


Vince Calio covers health care and manufacturing for NJBIZ. You can contact him at vcalio@njbiz.com.

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close